Recent studies have focused on the convergence of GLP|GIP|GCGR agonist therapies and DA communication. While GLP stimulators are increasingly employed for addressing type 2 T2DM, their potential consequences on reward circuits, specifically mediated by dopaminergic pathways, are gaining substantial interest. This article details a brief overview of